Description
CagriSema is an investigational once-weekly injectable combination therapy developed by Novo Nordisk, comprising cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. This dual-agent formulation targets multiple pathways involved in appetite regulation and energy balance, aiming to enhance weight loss and glycemic control in individuals with obesity or overweight, with or without type 2 diabetes. Cagrilintide acts on amylin and calcitonin receptors to promote satiety, while semaglutide enhances insulin secretion and delays gastric emptying.
Directions
CagriSema is administered via subcutaneous injection once weekly. In clinical trials, dosing regimens have included combinations such as 2.4 mg cagrilintide with 2.4 mg semaglutide. The optimal dosing strategy is under investigation, with titration protocols designed to balance efficacy and tolerability. Administration should be performed by trained healthcare professionals or patients educated in proper injection techniques. Injection sites should be rotated among the abdomen, thigh, or upper arm to minimize local reactions.
Ingredients
Each dose of CagriSema contains:
- Cagrilintide (dose varies per study protocol)
- Semaglutide (dose varies per study protocol)
- Excipients: disodium phosphate dihydrate, sodium chloride, hydrochloric acid, sodium hydroxide, and water for injection
Note: As CagriSema is currently investigational, the exact formulation may vary across clinical studies.
Contraindications
As CagriSema is under clinical investigation, comprehensive contraindication profiles are not yet established. However, based on the pharmacological classes of its components, potential contraindications may include:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to cagrilintide, semaglutide, or any formulation components
Cautions
Patients should be evaluated for risk factors associated with pancreatitis, gastrointestinal disorders, and renal impairment prior to initiation. Monitoring for signs of thyroid tumors is advised due to observed risks in rodent studies with GLP-1 receptor agonists. The safety of CagriSema during pregnancy and lactation has not been established; thus, it should be used during these periods only if the potential benefit justifies the potential risk.
Side Effects
Common side effects observed in clinical trials include:
Serious adverse effects may include:
- Hypoglycemia (especially when used with other glucose-lowering agents)
- Potential risk of thyroid C-cell tumors
Frequently Asked Questions about CagriSema
What is CagriSema?
CagriSema is a combination medication containing cagrilintide and semaglutide, designed for weight management and glycemic control in eligible patients.
How does CagriSema work?
CagriSema works through dual mechanisms: cagrilintide is an amylin analog that helps reduce appetite and food intake, while semaglutide is a GLP-1 receptor agonist that slows gastric emptying and improves insulin secretion.
Who is eligible for CagriSema treatment?
CagriSema is typically prescribed for adults with obesity (BMI =30) or overweight (BMI =27) with at least one weight-related comorbidity, particularly those with type 2 diabetes.
How is CagriSema administered?
CagriSema is administered as a once-weekly subcutaneous injection, with dosage typically starting low and gradually increasing over several weeks.
What are the common side effects of CagriSema?
Common side effects include nausea, vomiting, diarrhea, constipation, and injection site reactions. These typically decrease in severity over time.
Is CagriSema covered by insurance?
Insurance coverage varies by provider and plan. Patients should check with their insurance company regarding coverage details and prior authorization requirements.
Can CagriSema be used with other diabetes medications?
CagriSema may be used alongside certain diabetes medications, but dosage adjustments may be necessary. Always consult with your healthcare provider about potential drug interactions.
How long does it take to see results with CagriSema?
Most patients begin to notice weight loss within the first 4-8 weeks of treatment, with continued results over the following months when combined with lifestyle modifications.
What lifestyle changes should accompany CagriSema treatment?
CagriSema is most effective when combined with a reduced-calorie diet and increased physical activity as recommended by your healthcare provider.
What should I do if I miss a dose of CagriSema?
If you miss a dose and the next scheduled dose is more than 2 days away, take the missed dose as soon as possible. If the next scheduled dose is within 2 days, skip the missed dose and resume your regular dosing schedule.
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 14029
Prescription Required